Skip to content
Triangle logo TriangleGet started
← Study library

NCT05282459 · REGISTRY CONDITION SEARCH

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2026-09-03

This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Clinical Response: Hematological Improvement - Erythroid (HI-E)

→

outcome · POSTED

Related Adverse Events

→

outcome · POSTED

Time to Hematological Improvement - Erythroid (HI-E)

→

outcome · POSTED

Duration of Hematological Improvement - Erythroid (HI-E)

→

outcome · POSTED

Clinical Response: Hematological Improvement - Platelets (HI-P)

→

outcome · POSTED

Clinical Response: Hematological Improvement - Neutrophils (HI-N)

→

outcome · POSTED

Red Blood Cell (RBC) Transfusion Independence (RBC TI)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Documented diagnosis of * MDS according to WHO/FAB classification that meets IRSS-R classification of low or intermediate risk disease; and a diagnosed as denovo or secondary MDS (MDS-RS eligible if refractory to or declined luspatercept therapy) OR * Dysplastic (nonproliferative) CMML with WBC \< 13.0/microL) 2. No disease-modifying therapy (HMA, hydrea) within 2 months of starting study 3. Age ≥ 18 years of age 4. ECOG ≤ 3 5. Negative for IDH2 mutation by NGS or multiplex PCR (SNaPshot) 6. Has symptomatic anemia defined as hemoglobin \< 10.5 g/dL with any of the following. * Tachypnea * Shortness of breath * Fatigue * Malaise * Worsening of cardiovascular function * Asthenia * Dyspnea on exertion * Angina * Other subject symptoms the subject reports as being associated with being anemic. 7. Stated willingness to comply with all study procedures and availability for the duration of the study 8. Ability to take oral medication and be willing to adhere to the medication regimen. 9. Females of reproductive potential need to either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption, 28 days prior to starting enasidenib, during the study therapy, and for 30 days after last dose of enasidenib 10. For males of reproductive potential: agreement to use of condoms 11. Adequate organ function defined as: * Hepatic function: total bilirubin \<1.5 x ULN (unless attributable to Gilbert's disease), AST or ALT \< 3x ULN * Renal function: creatinine clearance \> 30 mL/minute, calculated by Cockcroft-Gault formula 12. Ability to understand and the willingness to sign the IRB approved informed consent document. 13. Women of childbearing potential must have negative urine or serum pregnancy test Exclusion Criteria: 1. Use of concurrent other erythropoietic agents (including epoetin, darbepoetin), G-CSF within 30 days of study enrollment 2. Less than 3 months of life expectancy 3. Significant cardiac disease (NYHA Class IV congestive heart failure, or unstable angina or myocardial infarction within the last 6 months 4. Harbor IDH2 somatic mutations by NGS or PCR 5. Pregnant or breast feeding 6. Any uncontrolled bacterial, fungal, viral or other infection. 7. No known HIV+ or active hepatitis B or C infection, defined as positive viral load for HBV or HCV or a positive surface antigen (HBsAg) test for hepatitis B. 8. Have other causes of anemia: deficiencies in iron, B12, folate; nutritional deficiencies related to gastric surgery, anorexia nervosa, excessive zinc supplementation; gastrointestinal bleed. If nutritional deficiencies can be corrected, potential subject can be rescreened and enrolled if nutritionally replete and still meets eligibility criteria. 9. Any other medical history, including laboratory results, deemed by the Principal Investigator likely to interfere with their participation in the study, or to interfere with the interpretation of the results 10. Pregnant or breast feeding
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants will self administer the enasidenib orally everyday.
    intervention Names
    1. Drug: Enasidenib mesylat dose escalation
    label
    Enasidenib mesylat
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Enasidenib mesylat
    description
    Subjects will participate dose escalation with a starting dose of 100 mg. Enasidenib will be self administered orally and daily.
    name
    Enasidenib mesylat dose escalation
    other Names
    1. (Idhifa, AG 221)
    type
    DRUG
Study design
allocation
NA
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
17
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Clinical response was assessed as the number of participants achieving a hematological improvement - erythroid (HI-E). Participants were characterized and stratified as nontransfused (NTD), low-transfusion burden (LTB) and high-transfusion burden (HTB), with response defined as follows. * NTD = greater than or equal to 2 consecutive Hb measurements, greater than or equal to 1.5 g/dL for a period of minimum 8 week in an observation period of 16 to 24 week compared to the lowest mean of 2 Hb measurements * LTB = 0 units of RBC transfusions * HTB = greater than or equal to 4 unit or greater than or equal to 50% reduction in RBC transfusions
    measure
    Clinical Response: Hematological Improvement - Erythroid (HI-E)
    time Frame
    16 weeks
secondary Outcomes
  1. description
    Toxicity was assessed as the number of related non-serious adverse events and related serious adverse events (SAEs) reported by dose level (Cohort A or Cohort B) for the 12-cycle treatment period plus follow-up.
    measure
    Related Adverse Events
    time Frame
    12 months
  2. description
    Time to hematological improvement - erythroid (HI-E) was assessed as the time from first dose of enasidenib to the first observed hemoglobin response. Participants will be characterized and stratified as non-transfused (NTD), low-transfusion burden (LTB) and high-transfusion burden (HTB), with response defined as follows. * NTD = greater than or equal to 2 consecutive Hb measurements, greater than or equal to 1.5 g/dL for a period of minimum 8 week in an observation period of 16 to 24 week compared to the lowest mean of 2 Hb measurements * LTB = 0 units of RBC transfusions * HTB = greater than or equal to 4 unit or greater than or equal to 50% reduction in RBC transfusions
    measure
    Time to Hematological Improvement - Erythroid (HI-E)
    time Frame
    16 weeks
  3. description
    Duration of Hematological Improvement - Erythroid (HI-E) will be assessed as the time from recorded response to loss of response. Participants will be characterized and stratified as nontransfused (NTD), low-transfusion burden (LTB) and high-transfusion burden (HTB), with response defined as follows. NTD = greater than or equal to 2 consecutive Hb measurements, greater than or equal to 1.5 g/dL for a period of minimum 8 week in an observation period of 16 to 24 week compared to the lowest mean of 2 Hb measurements LTB = 0 units of RBC transfusions HTB = greater than or equal to 4 unit or greater than or equal to 50% reduction in RBC transfusions The outcome will be reported as the number of participants that achieve the response, a number without dispersion.
    measure
    Duration of Hematological Improvement - Erythroid (HI-E)
    time Frame
    16 weeks
  4. description
    Clinical response for platelets was assessed as the number of participants achieving a hematological improvement - platelets (HI-P). Participants will be characterized and stratified as platelets \< or ≥ 20 x 10\^9/L, with response defined as follows. * \< 20 x 10\^9/L = increase in platelets from \< 20 x 10\^9/L to \> 20 x 10\^9/L AND by ≥ 100% * ≥ 20 x 10\^9/L = absolute increase in platelets of 30 x 10\^9/L The outcome will be reported as the number of participants that achieve the response, a number without dispersion.
    measure
    Clinical Response: Hematological Improvement - Platelets (HI-P)
    time Frame
    8 weeks
  5. description
    Clinical response for neutrophils was assessed as the number of participants achieving a hematological improvement - neutrophils (HI-N). Response was defined as an absolute increase in neutrophils \> 0.5 × 10\^9/L that was also an increase of ≥ 100%.
    measure
    Clinical Response: Hematological Improvement - Neutrophils (HI-N)
    time Frame
    8 weeks
  6. description
    Clinical response for red blood cells was assessed as the number of participants who were transfusion dependent that achieve red blood cell (RBC) transfusion independence (RBC TI) for for 8 weeks or longer.
    measure
    Red Blood Cell (RBC) Transfusion Independence (RBC TI)
    time Frame
    12 months
Full study description
brief Summary
This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.
detailed Description
Primary Objective(s)- To determine the efficacy (response rate) of enasidenib in improving anemia and decreasing RBC transfusion dependence. Secondary Objective(s)- To determine the tolerability, safety and durability of the erythroid response and identify laboratory parameters as clinical markers of response.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-9a22ac538fbd75633589
      requested nct id
      NCT05282459
      primary nct id
      NCT05282459
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      payload sha256
      1c9643da4d7f2ee8fba0dcae138ed0fd17af91942f80de71916aec693b90b254
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-9a22ac538fbd75633589
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT05282459
      occurrences
      1. context exact
        NCT05282459
        end
        11
        exact text
        NCT05282459
        start
        0
      offset unit
      unicode_code_points
      query cond
      Juvenile Myelomonocytic Leukemia
      query disease state id
      ds-juvenile-myelomonocytic-leukemia
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
      source file sha256
      cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
      source json pointer
      /studies/143/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      20cd9c119b86ac93ef870b5c51de8812e3d77ae9b77be9a44b055f80b2e07529

    Preserved source evidence · Not medical advice